Docoh
Loading...

OSMT Osmotica Pharmaceuticals

APP
Utility
Controlled Release Dosage Form with Enhanced Pharmacokinetics
16 Sep 21
The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof.
Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Claude E. WRIGHT
Filed: 5 Apr 21
GRANT
Utility
Oxymetazoline compositions
31 Aug 21
The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long term storage.
Tina deVries, David Jacobs
Filed: 21 Jan 21
GRANT
Utility
Controlled release dosage form
17 Aug 21
The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof.
Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Alejandro A. Aguilar, Claude E. Wright
Filed: 24 Feb 20
APP
Utility
Compositions and Methods for Treating Ocular Disorders
15 Jul 21
The present disclosure is directed to compositions comprising oxymetazoline and methods of treating various eye disorders related to drooping eyelids, such as ptosis, in a subject comprising administering to the subject compositions comprising oxymetazoline.
Tina deVries, David Jacobs
Filed: 8 Mar 21
APP
Utility
Oxymetazoline Compositions
13 May 21
The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long term storage.
Tina deVries, David Jacobs
Filed: 21 Jan 21
GRANT
Utility
Controlled release dosage form with enhanced pharmacokinetics
27 Apr 21
The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof.
Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Claude E. Wright
Filed: 31 Dec 19
GRANT
Utility
Controlled release dosage form
27 Apr 21
The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof.
Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Alejandro A. Aguilar, Claude E. Wright
Filed: 10 Apr 19
GRANT
Utility
Dose-dumping resistant controlled release dosage form
29 Jun 20
The present invention provides a simple and improved dosage form that provides a controlled release of methylphenidate contained in the core thereof.
Hernan D. Benedetti, Cristian R. Franco, Guido S. Bigatti, Joaquina Faour, Ana C. Pastini
Filed: 5 Feb 19
APP
Utility
Controlled Release Dosage Form
17 Jun 20
The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof.
Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Alejandro A. AGUILAR, Claude E. WRIGHT
Filed: 23 Feb 20
APP
Utility
Controlled Release Dosage Form with Enhanced Pharmacokinetics
29 Apr 20
The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof.
Glenn A. MEYER, Cristian R. FRANCO, Gustavo A. FISCHBEIN, Claude E. WRIGHT
Filed: 30 Dec 19
GRANT
Utility
Controlled release dosage form
6 Apr 20
The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof.
Glenn A. Meyer, Cristian R. Franco, Gustavo A. Fischbein, Alejandro A. Aguilar, Claude E. Wright
Filed: 5 Dec 18
  • 1
Patents are sorted by USPTO publication date, most recent first